- Home
- NOTE vs RLMD Comparison
NOTE vs RLMD Comparison
Compare NOTE & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOTE
- RLMD
- Stock Information
- Founded
- NOTE 2013
- RLMD 2004
- Country
- NOTE United States
- RLMD United States
- Employees
- NOTE N/A
- RLMD N/A
- Industry
- NOTE EDP Services
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- NOTE Technology
- RLMD Health Care
- Exchange
- NOTE Nasdaq
- RLMD Nasdaq
- Market Cap
- NOTE 132.5M
- RLMD 110.6M
- IPO Year
- NOTE N/A
- RLMD N/A
- Fundamental
- Price
- NOTE $1.05
- RLMD $0.36
- Analyst Decision
- NOTE Strong Buy
- RLMD Hold
- Analyst Count
- NOTE 6
- RLMD 3
- Target Price
- NOTE $3.30
- RLMD $5.33
- AVG Volume (30 Days)
- NOTE 1.1M
- RLMD 2.1M
- Earning Date
- NOTE 11-12-2024
- RLMD 11-07-2024
- Dividend Yield
- NOTE N/A
- RLMD N/A
- EPS Growth
- NOTE N/A
- RLMD N/A
- EPS
- NOTE N/A
- RLMD N/A
- Revenue
- NOTE $125,062,000.00
- RLMD N/A
- Revenue This Year
- NOTE N/A
- RLMD N/A
- Revenue Next Year
- NOTE $4.01
- RLMD N/A
- P/E Ratio
- NOTE N/A
- RLMD N/A
- Revenue Growth
- NOTE N/A
- RLMD N/A
- 52 Week Low
- NOTE $0.75
- RLMD $0.35
- 52 Week High
- NOTE $2.27
- RLMD $7.22
- Technical
- Relative Strength Index (RSI)
- NOTE 56.71
- RLMD 16.59
- Support Level
- NOTE $0.81
- RLMD $0.35
- Resistance Level
- NOTE $0.95
- RLMD $0.41
- Average True Range (ATR)
- NOTE 0.12
- RLMD 0.16
- MACD
- NOTE 0.03
- RLMD -0.11
- Stochastic Oscillator
- NOTE 67.57
- RLMD 0.38
About NOTE FiscalNote Holdings Inc.
FiscalNote Holdings Inc is a provider of global policy and market intelligence solutions. Leveraging AI and analytics, it delivers actionable legal and policy insights for businesses, government institutions, and nonprofits. Its suite of products includes FiscalNote Core, CQ Federal, and EU Issue Tracker, facilitating effective policy management and risk mitigation. With expert analysis from FrontierView, Oxford Analytica, and Dragonfly Eye, it offers geopolitical and market intelligence services. Operating as one segment, it generates revenue by integrating policy intelligence into daily operations. Geographically the company generates the majority of its revenue from North America, Europe, Australia, and Asia, with the majority generated from North America.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.